Elicio Therapeutics
Most recent annual filing: 2026-03-12
Pipeline (6 active programs)
ELI-002 2P
ELI-002 7P
ELI-007
- Undisclosed indication
ELI-008
- Undisclosed indication
ELI-004
Technology platforms
AMP · MIT
Amphiphile (AMP) technology — lymph node-targeted delivery platform using albumin hitchhiking to deliver peptides, proteins, nucleic acids and small molecules to lymph nodes; applications in cancer immunotherapy (mKRAS, BRAF, TP53 neoantigen vaccines), CAR-T and TCR-T cell therapy enhancement, prophylactic vaccines, and autoimmune disease
Targets: KRAS, BRAF, TP53
AMP
Amphiphilic lipid-modified (AMP) delivery platform that targets immunotherapy directly to lymph nodes via albumin trafficking; originally developed at MIT; enables delivery of disease-specific antigens, adjuvants, and immunomodulators to drive adaptive immunity; broad oncology focus including mKRAS-driven and BRAF-driven cancers and p53 hotspot mutations.
Targets: KRAS, BRAF, p53
Biotech Distilled coverage (5)
- 2026-07-02 UPDATE: Elicio Therapeutics (ELTX) - The Financing Tell Landed
- 2026-06-24 UPDATE: Elicio Therapeutics (ELTX) - The KOLs Showed Up, the Checkbook Didn’t
- 2026-06-17 UPDATE: Elicio Therapeutics (ELTX) - Three Complete Responses and a Lifeline Narrative
- 2026-06-15 UPDATE: Elicio Therapeutics (ELTX) - The Binary Broke
- 2026-06-12 Elicio Therapeutics (ELTX) - Scientific Deep Dive for ELI-002 7P and the AMP Pipeline
Articles open on Substack. Some deep dives are subscriber-only.